Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

191 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis. Austrian Immunoglobulin in Multiple Sclerosis Study Group.
Fazekas F, Deisenhammer F, Strasser-Fuchs S, Nahler G, Mamoli B. Fazekas F, et al. Among authors: deisenhammer f. Lancet. 1997 Mar 1;349(9052):589-93. doi: 10.1016/s0140-6736(96)09377-4. Lancet. 1997. PMID: 9057729 Clinical Trial.
Treatment effects of monthly intravenous immunoglobulin on patients with relapsing-remitting multiple sclerosis: further analyses of the Austrian Immunoglobulin in MS study.
Fazekas F, Deisenhammer F, Strasser-Fuchs S, Nahler G, Mamoli B. Fazekas F, et al. Among authors: deisenhammer f. Mult Scler. 1997 Apr;3(2):137-41. doi: 10.1177/135245859700300214. Mult Scler. 1997. PMID: 9291168 Clinical Trial.
Bioavailability of interferon beta 1b in MS patients with and without neutralizing antibodies.
Deisenhammer F, Reindl M, Harvey J, Gasse T, Dilitz E, Berger T. Deisenhammer F, et al. Neurology. 1999 Apr 12;52(6):1239-43. doi: 10.1212/wnl.52.6.1239. Neurology. 1999. PMID: 10214750
Interferon-beta 1b augments activation-induced T-cell death in multiple sclerosis patients.
Kaser A, Deisenhammer F, Berger T, Tilg H. Kaser A, et al. Among authors: deisenhammer f. Lancet. 1999 Apr 24;353(9162):1413-4. doi: 10.1016/S0140-6736(99)00622-4. Lancet. 1999. PMID: 10227230 No abstract available.
Antibodies against the myelin oligodendrocyte glycoprotein and the myelin basic protein in multiple sclerosis and other neurological diseases: a comparative study.
Reindl M, Linington C, Brehm U, Egg R, Dilitz E, Deisenhammer F, Poewe W, Berger T. Reindl M, et al. Among authors: deisenhammer f. Brain. 1999 Nov;122 ( Pt 11):2047-56. doi: 10.1093/brain/122.11.2047. Brain. 1999. PMID: 10545390 Clinical Trial.
A comparative study of the relative bioavailability of different interferon beta preparations.
Deisenhammer F, Mayringer I, Harvey J, Dilitz E, Gasse T, Stadlbauer D, Reindl M, Berger T. Deisenhammer F, et al. Neurology. 2000 Jun 13;54(11):2055-60. doi: 10.1212/wnl.54.11.2055. Neurology. 2000. PMID: 10851362 Clinical Trial.
The Austrian Immunoglobulin in MS (AIMS) study: final analysis.
Strasser-Fuchs S, Fazekas F, Deisenhammer F, Nahler G, Mamoli B. Strasser-Fuchs S, et al. Among authors: deisenhammer f. Mult Scler. 2000 Oct;6 Suppl 2:S9-13. Mult Scler. 2000. PMID: 11188778 Clinical Trial.
Increased intrathecal production of apolipoprotein D in multiple sclerosis.
Reindl M, Knipping G, Wicher I, Dilitz E, Egg R, Deisenhammer F, Berger T. Reindl M, et al. Among authors: deisenhammer f. J Neuroimmunol. 2001 Oct 1;119(2):327-32. doi: 10.1016/s0165-5728(01)00378-2. J Neuroimmunol. 2001. PMID: 11585636
Anti-MOG and anti-MBP antibody subclasses in multiple sclerosis.
Egg R, Reindl M, Deisenhammer F, Linington C, Berger T. Egg R, et al. Among authors: deisenhammer f. Mult Scler. 2001 Oct;7(5):285-9. doi: 10.1177/135245850100700503. Mult Scler. 2001. PMID: 11724443
A novel and rapid assay for the detection of neutralizing antibodies against interferon-beta.
Kob M, Harvey J, Schautzer F, Kascha S, Bibl D, Egg R, Reindl M, Berger T, Deisenhammer F. Kob M, et al. Among authors: deisenhammer f. Mult Scler. 2003 Feb;9(1):32-5. doi: 10.1191/1352458503ms889oa. Mult Scler. 2003. PMID: 12617265
191 results
Jump to page
Feedback